BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Alsaif NA, Taghour MS, Alanazi MM, Obaidullah AJ, Al-Mehizia AA, Alanazi MM, Aldawas S, Elwan A, Elkady H. Discovery of new VEGFR-2 inhibitors based on bis([1, 2, 4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as anticancer agents and apoptosis inducers. J Enzyme Inhib Med Chem 2021;36:1093-114. [PMID: 34056992 DOI: 10.1080/14756366.2021.1915303] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Taghour MS, Elkady H, Eldehna WM, El-Deeb NM, Kenawy AM, Elkaeed EB, Alsfouk AA, Alesawy MS, Metwaly AM, Eissa IH. Design and synthesis of thiazolidine-2,4-diones hybrids with 1,2-dihydroquinolones and 2-oxindoles as potential VEGFR-2 inhibitors: in-vitro anticancer evaluation and in-silico studies. J Enzyme Inhib Med Chem 2022;37:1903-17. [PMID: 35801403 DOI: 10.1080/14756366.2022.2085693] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
2 Nossier ES, Alasfoury RA, Hagras M, El-manawaty M, Sayed SM, Ibrahim IM, Elkady H, Eissa IH, Elzahabi HS. Modified pyrido[2,3-d]pyrimidin-4(3H)-one derivatives as EGFRWT and EGFRT790M inhibitors: Design, synthesis, and anti-cancer evaluation. Journal of Molecular Structure 2022;1270:133971. [DOI: 10.1016/j.molstruc.2022.133971] [Reference Citation Analysis]
3 Taghour MS, Mahdy HA, Gomaa MH, Aglan A, Eldeib MG, Elwan A, Dahab MA, Elkaeed EB, Alsfouk AA, Khalifa MM, Eissa IH, Elkady H. Benzoxazole derivatives as new VEGFR-2 inhibitors and apoptosis inducers: design, synthesis, in silico studies, and antiproliferative evaluation. J Enzyme Inhib Med Chem 2022;37:2063-77. [PMID: 35875937 DOI: 10.1080/14756366.2022.2103552] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Belal A, Abdel Gawad NM, Mehany ABM, Abourehab MAS, Elkady H, Al-Karmalawy AA, Ismael AS. Design, synthesis and molecular docking of new fused 1H-pyrroles, pyrrolo[3,2-d]pyrimidines and pyrrolo[3,2-e][1, 4]diazepine derivatives as potent EGFR/CDK2 inhibitors. J Enzyme Inhib Med Chem 2022;37:1884-902. [PMID: 35801486 DOI: 10.1080/14756366.2022.2096019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
5 Belal A, Elkady H, Al-karmalawy AA, Amin AH, Ghoneim MM, El-sherbiny M, Al-serwi RH, Abdou MA, Ibrahim MH, Mehany ABM. Discovery of Some Heterocyclic Molecules as Bone Morphogenetic Protein 2 (BMP-2)-Inducible Kinase Inhibitors: Virtual Screening, ADME Properties, and Molecular Docking Simulations. Molecules 2022;27:5571. [DOI: 10.3390/molecules27175571] [Reference Citation Analysis]
6 Metwaly AM, Elwan A, El-attar AMM, Al-rashood ST, Eissa IH, Singh AK. Structure-Based Virtual Screening, Docking, ADMET, Molecular Dynamics, and MM-PBSA Calculations for the Discovery of Potential Natural SARS-CoV-2 Helicase Inhibitors from the Traditional Chinese Medicine. Journal of Chemistry 2022;2022:1-23. [DOI: 10.1155/2022/7270094] [Reference Citation Analysis]
7 Elwan A, Abdallah AE, Mahdy HA, Dahab MA, Taghour MS, Elkaeed EB, Mehany ABM, Nabeeh A, Adel M, Alsfouk AA, Elkady H, Eissa IH. Modified Benzoxazole-Based VEGFR-2 Inhibitors and Apoptosis Inducers: Design, Synthesis, and Anti-Proliferative Evaluation. Molecules 2022;27:5047. [PMID: 35956997 DOI: 10.3390/molecules27155047] [Reference Citation Analysis]
8 Salem MG, El-Maaty DMA, El-Deen YIM, Elesawy BH, Askary AE, Saleh A, Saied EM, Behery ME. Novel 1,3-Thiazole Analogues with Potent Activity against Breast Cancer: A Design, Synthesis, In Vitro, and In Silico Study. Molecules 2022;27:4898. [PMID: 35956848 DOI: 10.3390/molecules27154898] [Reference Citation Analysis]
9 Elkaeed EB, Yousef RG, Elkady H, Gobaara IMM, Alsfouk AA, Husein DZ, Ibrahim IM, Metwaly AM, Eissa IH. The Assessment of Anticancer and VEGFR-2 Inhibitory Activities of a New 1H-Indole Derivative: In Silico and In Vitro Approaches. Processes 2022;10:1391. [DOI: 10.3390/pr10071391] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
10 Azab AE, Alesawy MS, Eldehna WM, Elwan A, Eissa IH. New [1,2,4]triazolo[4,3-c]quinazoline derivatives as vascular endothelial growth factor receptor-2 inhibitors and apoptosis inducers: Design, synthesis, docking, and antiproliferative evaluation. Arch Pharm (Weinheim) 2022;:e2200133. [PMID: 35822666 DOI: 10.1002/ardp.202200133] [Reference Citation Analysis]
11 Elkaeed EB, Youssef FS, Eissa IH, Elkady H, Alsfouk AA, Ashour ML, El Hassab MA, Abou-seri SM, Metwaly AM. Multi-Step In Silico Discovery of Natural Drugs against COVID-19 Targeting Main Protease. IJMS 2022;23:6912. [DOI: 10.3390/ijms23136912] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
12 Eissa IH, El-Haggar R, Dahab MA, Ahmed MF, Mahdy HA, Alsantali RI, Elwan A, Masurier N, Fatahala SS. Design, synthesis, molecular modeling and biological evaluation of novel Benzoxazole-Benzamide conjugates via a 2-Thioacetamido linker as potential anti-proliferative agents, VEGFR-2 inhibitors and apoptotic inducers. J Enzyme Inhib Med Chem 2022;37:1587-99. [PMID: 35637622 DOI: 10.1080/14756366.2022.2081844] [Reference Citation Analysis]
13 Alanazi MM, Elkady H, Alsaif NA, Obaidullah AJ, Alanazi WA, Al-hossaini AM, Alharbi MA, Eissa IH, Dahab MA. Discovery of new quinoxaline-based derivatives as anticancer agents and potent VEGFR-2 inhibitors: Design, synthesis, and in silico study. Journal of Molecular Structure 2022;1253:132220. [DOI: 10.1016/j.molstruc.2021.132220] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
14 Huang Q, Wang X, Cheng A, Zhang H, Yu Q, Shen C, Awadasseid A, Zhao X, Xiong X, Wu Y, Zhang W. Design, synthesis and anti-tumor activity of novel benzothiophenonaphthalimide derivatives targeting mitochondrial DNA (mtDNA) G-quadruplex. Biochemical Pharmacology 2022. [DOI: 10.1016/j.bcp.2022.115062] [Reference Citation Analysis]
15 Elkaeed EB, Elkady H, Belal A, Alsfouk BA, Ibrahim TH, Abdelmoaty M, Arafa RK, Metwaly AM, Eissa IH. Multi-Phase In Silico Discovery of Potential SARS-CoV-2 RNA-Dependent RNA Polymerase Inhibitors among 3009 Clinical and FDA-Approved Related Drugs. Processes 2022;10:530. [DOI: 10.3390/pr10030530] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 13.0] [Reference Citation Analysis]
16 Elkady H, Elwan A, El-Mahdy HA, Doghish AS, Ismail A, Taghour MS, Elkaeed EB, Eissa IH, Dahab MA, Mahdy HA, Khalifa MM. New benzoxazole derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: design, synthesis, anti-proliferative evaluation, flowcytometric analysis, and in silico studies. J Enzyme Inhib Med Chem 2022;37:397-410. [PMID: 34961427 DOI: 10.1080/14756366.2021.2015343] [Reference Citation Analysis]
17 Alsaif NA, Mahdy HA, Alanazi MM, Obaidullah AJ, Alkahtani HM, Al-Hossaini AM, Al-Mehizi AA, Elwan A, Taghour MS. Targeting VEGFR-2 by new quinoxaline derivatives: Design, synthesis, antiproliferative assay, apoptosis induction, and in silico studies. Arch Pharm (Weinheim) 2021;:e2100359. [PMID: 34862634 DOI: 10.1002/ardp.202100359] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
18 Alesawy MS, Elkaeed EB, Alsfouk AA, Metwaly AM, Eissa IH. In Silico Screening of Semi-Synthesized Compounds as Potential Inhibitors for SARS-CoV-2 Papain-like Protease: Pharmacophoric Features, Molecular Docking, ADMET, Toxicity and DFT Studies. Molecules 2021;26:6593. [PMID: 34771004 DOI: 10.3390/molecules26216593] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
19 Eissa IH, Khalifa MM, Elkaeed EB, Hafez EE, Alsfouk AA, Metwaly AM. In Silico Exploration of Potential Natural Inhibitors against SARS-Cov-2 nsp10. Molecules 2021;26:6151. [PMID: 34684735 DOI: 10.3390/molecules26206151] [Cited by in Crossref: 1] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
20 Alsaif NA, Taghour MS, Alanazi MM, Obaidullah AJ, Alanazi WA, Alasmari A, Albassam H, Dahab MA, Mahdy HA. Identification of new [1,2,4]triazolo[4,3-a]quinoxalines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, anticancer evaluation, and in silico studies. Bioorg Med Chem 2021;46:116384. [PMID: 34479065 DOI: 10.1016/j.bmc.2021.116384] [Reference Citation Analysis]
21 Alanazi MM, Elkady H, Alsaif NA, Obaidullah AJ, Alkahtani HM, Alanazi MM, Alharbi MA, Eissa IH, Dahab MA. New quinoxaline-based VEGFR-2 inhibitors: design, synthesis, and antiproliferative evaluation with in silico docking, ADMET, toxicity, and DFT studies. RSC Adv 2021;11:30315-28. [PMID: 35493991 DOI: 10.1039/d1ra05925d] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
22 Alsaif NA, Elwan A, Alanazi MM, Obaidullah AJ, Alanazi WA, Alasmari AF, Albassam H, Mahdy HA, Taghour MS. Design, synthesis and molecular docking of new [1,2,4] triazolo[4,3-a]quinoxaline derivatives as anticancer agents targeting VEGFR-2 kinase. Mol Divers 2021. [PMID: 34460053 DOI: 10.1007/s11030-021-10303-6] [Reference Citation Analysis]
23 Alanazi MM, Alaa E, Alsaif NA, Obaidullah AJ, Alkahtani HM, Al-Mehizia AA, Alsubaie SM, Taghour MS, Eissa IH. Discovery of new 3-methylquinoxalines as potential anti-cancer agents and apoptosis inducers targeting VEGFR-2: design, synthesis, and in silico studies. J Enzyme Inhib Med Chem 2021;36:1732-50. [PMID: 34325596 DOI: 10.1080/14756366.2021.1945591] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Abdallah AE, Alesawy MS, Eissa SI, El-fakharany EM, Kalaba MH, Sharaf MH, Abo Shama NM, Mahmoud SH, Mostafa A, Al-karmalawy AA, Elkady H. Design and synthesis of new 4-(2-nitrophenoxy)benzamide derivatives as potential antiviral agents: molecular modeling and in vitro antiviral screening. New J Chem 2021;45:16557-71. [DOI: 10.1039/d1nj02710g] [Cited by in Crossref: 30] [Cited by in F6Publishing: 18] [Article Influence: 30.0] [Reference Citation Analysis]